



Public Utility and Telecommunications Consulting

David W. Rolka
President
Voice: 717-585-6605
Ex 602
drolka@rolkaloube.com
www.rolkaloube.com

May 22, 2018

Re: Confidential Request for Ex Parte Written Communications Regarding 2018 TRS Fund
Annual Report submitted at CG Docket No. 03-123 and CG Docket No 10-51

Marlene H. Dortch
Secretary
Federal Communications Commission
445 12th Street, SW
Washington D.C. 20554

Dear Ms. Dortch:

Pursuant to 47 C.F.R. § 0.459 Rolka Loube Associates serving in its capacity as the Administrator of the Interstate Telecommunications Relay Service Fund (TRS Fund), hereby requests confidential treatment for the attached document, revised Exhibit 1-3.1 of the Administrator's report, Interstate Telecommunications Relay Services Fund Payment Formula and Fund Size Estimate for Fund Year 2018-2019 (2018 Annual Report). The attached document contains company specific, confidential financial data submitted to Rolka Loube Associates serving in its capacity as the Administrator of the Interstate Telecommunications Fund and relied on in making a recommendation to the Federal Communications Commission regarding the reimbursement rate applicable to Internet Protocol Captioned Telephone Service (IP CTS).

1. *Identification of the specific information for which confidential treatment is sought.* The data attached to this request for confidential treatment is the reported costs and minutes of use of service reported to Rolka Loube Associates by service providers, Sorenson (CaptionCall), Hamilton, Sprint, ClearCaption, and InnoCaption (previously Miracom), which are not otherwise publicly available.
2. *Identification of the Commission proceeding in which the information was submitted or a description of the circumstances giving rise to the submission.* Rolka Loube Associates have submitted the 2018 Annual Report at CG Docket No 03-123 and CG Docket No. 10-51 containing recommendations for TRS Fund service reimbursement rates which in all cases except for IP Relay service and Emergent VRS service are the product of aggregate data supplied by more than two service providers.
3. *Explanation of the degree to which the information is commercial or financial, or contains a trade secret or is privileged.* The data attached to this request for confidential treatment is the reported costs and demand for service reported to Rolka Loube Associates by service providers, Sorenson (CaptionCall), Hamilton, Sprint, ClearCaption,

and InnoCaption (previously Miracom), which are commercial or financial information and not otherwise publicly available.

4. *Explanation of the degree to which the information concerns a service that is subject to competition.* The data attached to this request for confidential treatment has been requested by the Consumer and Governmental Affairs Bureau in support of the recommended reimbursement rate for IP CTS. These providers compete with one another in the provision of IP CTS.
5. *Explanation of how disclosure of the information could result in substantial competitive harm.* Because this type of information is not subject to public inspection and is guarded from potential competitors, the Commission's rules recognize that the release of the information is likely to produce competitive harm.
6. *Identification of any measures taken by the submitting party to prevent unauthorized disclosure.* The information in the attached document is not readily available to the public and is a reporting requirement of the TRS Fund Administrator and the Commission.
7. *Identification of whether the information is available to the public and the extent of any previous disclosure of the information to third parties.* The information in the attached document is not readily available to the public and has been submitted to the TRS Fund Administrator as a reporting requirement of the TRS Fund Administrator and the Commission.
8. *Justification of the period during which the submitting party asserts that the material should not be available for public disclosure.* Rolka Loube Associates requests that the attached information be treated as confidential indefinitely, as it is not possible to determine at this time any date certain by which the information could be disclosed without risk of harm.
9. *Any other information that the party seeking confidential treatment believes may be useful in assessing whether its request for confidentiality should be granted.* The confidential information contained in the attachment would if publicly disclosed potentially enable an IP CTS provider's competitors to gain an unfair advantage. Under applicable Commission and federal court precedent, the information provided to the TRS Fund Administrator on a confidential basis should be shielded from public disclosure.

Sincerely,



David Rolka, President

TRS Fund Administrator